FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Narula Sanjeev					2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last)	,	rst) (Middle) JLAR THERAPIES, INC.				3. Date of Earliest Transaction (Month/Day/Year) 08/12/2024							Officer (give title below) Executive Vice President & CFO					
430 EAST 29TH STREET					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) NEW Y	ORK N	Y	10016											iled by Mor		rting Persor One Repor		
(City) (State) (Zip)					R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tah	le I - Non	ı-Deriv	/ativ													
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				action	action 2A. Deemed Execution Date,		Code (Instr. 5)			ed (A) or	5. Amour Securitie Beneficia Owned F	nt of s ally following	Form:	Direct Condition of the Direct	7. Nature of Indirect Beneficial Ownership			
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution D if any (Month/Day/	Date, Transactio Code (Inst					6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$74.9	08/12/2024			Α		17,251		(1)	08/11/2034	Common Stock	17,251	\$0.00	17,251		D		
Restricted Stock Units	(2)	08/12/2024			A		35,046		(3)	(3)	Common Stock	35,046	\$0.00	35,046	5	D		

Explanation of Responses:

- 1. The option vests as to one third of the shares on August 12, 2025, one third of the shares on August 12, 2026 and one third of the shares on August 12, 2027.
- 2. Each restricted stock unit represents a contingent right to receive one share of common stock.
- 3. The restricted stock units vest as to one third of the shares on August 12, 2025, one third of the shares on August 12, 2026 and one third of the shares on August 12, 2027.

/s/ John P. Condon, Attorneyin-fact 08/14/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.